WO1996032952A1

WO1996032952A1 - Caffeine composition as medicament and use thereof

Info

Publication number: WO1996032952A1
Application number: PCT/NZ1996/000032
Authority: WO
Inventors: Oswald Edmonds Hooper
Original assignee: Oswald Edmonds Hooper
Priority date: 1995-04-21
Filing date: 1996-04-18
Publication date: 1996-10-24

Abstract

A medicament suitable for the treatment of mammals for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated and/or for the use as a detoxicant mixture with any such mammal, said medicament comprising or including: caffeine (anhydrous) about 20 g/l; potassium iodide about 20 g/l and ammonium chloride about 20 g/l.

Description

CafFeine composition as medicament and use thereof

TECHNICAL FIELD

The present invention relates to a medicament for treating humans for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated. BACKGROUND ART

In my US Patent Specification No.5275828, the full contents of which are hereby here included by way of reference, there is disclosed and claimed a medicament comprising an effective amount of a mixture of potassium iodide, ammonium chloride and caffeine for treating viral infections and bacterial infections commonly associated therewith. In particular there is disclosure of the use of such a composition for treating equine viral infections and bacterial infections commonly associated therewith.

A preferred medicament disclosed and claimed in the aforementioned specification comprised potassium iodide 200 mg/L to 800 mg/L ammonium chloride 200 mg/L to about 800 mg L, and caffeine 200 mg/L to about 800 mg/L.

A particularly preferred medicament of the aforementioned US Patent specification 5275828 additionally included aqueous chloroform 10 ml/L to about 40 ml L.

There is also disclosure of administration of such a composition in an amount between about 30 ml and 120 ml on a daily basis.

The medicament of my US Patent specification 5275828 was applied both to unhealthy and well as healthy horses. Encouraged by the success of a medicament as disclosed in US patent specification

5275828 in respect of the treatment of horses as well as other animals such as cats, dogs, calves and humans, I have now turned to formulating a form of the medicament suitable for use with humans. DISCLOSURE OF INVENTION Accordingly in a first aspect the present invention may broadly be said to consist in a medicament comprising or including

Caffeine (Anhydrous) about 2.0g/ 100ml Potassium Iodide about 2.0g/100ml and

Ammonium Chloride about 2.0g/ 100ml.

In a preferred form of the present invention the medicament comprises or includes Caffeine (Anhydrous) about 2.0g/ 100ml

Potassium Iodide about 2.0g/100ml

Ammonium Chloride about 2.0g/100ml

Methyl Paraben about lOOmg/ 100ml and

IIssoopprrooppyyll PPaarraabbeenn aabboouutt 50mg 100ml.

In a preferred form of the present invention the medicament comprises - Caffeine (Anhydrous) about 2.0g/ 100ml

Potassium Iodide about 2.0g/100ml

Ammonium Chloride about 2.0g/100ml M Meetthhyyll PPaarraabbeenn aabboouutt lOOmg/lOOml

Isopropyl Paraben about 50mg/100ml

Glycuol BP about 12.5g/100ml

Syrupus BP about 40g/100ml

Alcohol WS 95 about 5.7g/100ml G Grreeeenn NNoo..55 11%% ssoollnn aabboouutt 0.5g/100ml

In a further aspect the present invention consists in a medicament suitable for the treatment of mammals for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated and/or for the use as a detoxicant mixture with any such mammal, said medicament comprising or including Caffeine (anhydrous) about 20g L

Potassium Iodide about 20g/L, and

Ammonium chloride about 20g/L.

Preferably said medicament also includes: Methyl paraben and isopropyl paraben together with compatible carriers and orally acceptable inclusions. In yet a further aspect the present invention consists in a method of treating a human or mammal for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated and/or for detoxifying such a mammal, said method comprising the steps of periodically administering or having administered to such a mammalian patient an effective amount of a medicament comprising caffeine (anhydrous) about 20g/L, potassium iodide about 20g/L and ammonium chloride about 20g/L.

Preferably said medicament also includes methyl paraben and isopropyl paraben together with optionally compatible carriers and orally acceptable inclusions.

Preferably in the case of a human, a daily optimum dosage of about lml 6Kg of body weight is administered daily after a lead up period of lower dosing. DETAILED DESCRIPTION OF THE INVENTION Table 1

HUMAN

PROBLEM DOSE/ RESULT SIDE EFFECTS APPROXIMATE PATIENT SEX DAY DURING DURATION OF AGE TREATMENT TREATMENT (YEARS)

(MONTHS)

Bronchitis lOmls - No Bronchitis Runny Nose, 3 Months 52 F lSmls No Chest Pain Phlegm, Weight Increase

Blood lOmls No Headaches 1 Month 47 M

Pressure Decreased

Headaches Blood Pressure to Normal

Nausea, lOmls Lost all of 1 Month 40 M Headaches, Problems Cough Lethargy

Bad Hearing 2mls Normal Runny Nose, 1 Vi Months 4'/. M Glue Ear Hearing Mucus Mucus Cleared

Wheezing, 3 mis Easy Breathing 1 Month 7 M Bad at Breathing, Asthma Emphysema lOmls Much Pimples on Head 1 Month 63 M (lungs) Improved and Bade Breathing, Side Effects Cleared

Short of lOmls Clear lungs & 3 Months 49 M Breath, Sores Emphysema, Psoriasis

Asthma lSmls Good Mucus, Nasal 4V. Months 47 M

Using Breathing No Discharge

Inhailer need for inhaler

Tiredness, variable All Problems Nasal Discharge, 2 Months ? F Asthma Gone Pimples

Asthma lOmls Improved Weight Loss 2 Months 44 F

Bronchial lOmls Improved Does Nasal Discharge 4 Months 77 F Asthma Not Use Inhaler Anymore

Herpes on lOmls No Herpes nor Nasal Discharge, 1 '/. Months. Still 52 M Lips, Flu, Brucellosis Pimples on Back, healthy after 3 Headaches Muscle Weakness years from time of treatment

Flu, 30mls Sleep Better, Runny Nose 2 Months 36 F Headaches No Problems, Quick

Recovery from Flu

Tired 30mls Feel Better Constipated 1 Month 58 F

Flu lOmls Quick Runny Nose 2 Months 42 M Recovery

Runny 5mls All Problems 1 Month 8 M Nose/Cough Gone

Runny Smls All Problems 1 Month 35 M Nose/Cough Gone

Flu lOmls All Problems 1 Month 17 F Gone Cold Sores lOmls Less Tired, Rash on Back 2 Months 27 F More Energy

Shingles 5 - lOmls Problem Gone 5 Months 66 M

Shingles, lOmls More Energy, 3 Months 65 M Sores Rashes Gone

Tiredness, lOmls Rashes Gone, Pimple Outbreak 3 Months 36 F Psoriases, No Coldsores Headaches or Headaches

SLE 15mls Energy This is a medical 12 Months 38 M Increase and riddle . Now felt better healthy.

ME CFS 10 - Energy Discharge from Continuing. Now 28 M PUS 15mls Increase, Much Nose 98% cured on golf Improved cours 5 days a week.

Jaundice, 15mls Impotence Nasal Discharge 2 Months 56 M Sore Joints, Cured, No Tiredness Pain, Energy Increase

Bronchitis 10 - Much Continuing 59 F 12mls Improved

Lead lOmls Feeling Better Aching Stomach 3 Months 39 F

Poisoning Fibroid gone Muscles

Menopause

Prostate lOmls Normal 11 Months 78 M

Gland Urination,

Malfunction Energy Increase

Chronic 5mls Sinus Cleared, 2 Months 52 F Sinus Sleeping Better

Problem for Years

Hepatitis C 15mls Help Nausea, Sweats 2 Months 39 M

Eczema 5mls All Areas 2 Months 9 F about Mouth, Almost Chest and Cleared Back Lymphatic lOmls Haemoglobin Had had maximum 3 Months 60 M Cancer rose from 12.4 chemotherapy. to 15.9 3 years since [normal is 12 treatment - feels to 18] and 100% white cells dropped from 9.7 to 5.6 [normal is 4 to 11]

Prostate lOmls Prostate Feels better. 2¹/. Months 74 M Cancer specific antigen lowered from 37.6 to 0.9 [normal is 0 to 4]

Diabetes lOmls sSugar level Feels better and 5 Months 74 M dropped from more energetic. 13.1 to 9.0 [normal is 5 to 8]

The composition of the present invention was taken by human subjects on a daily basis. Each subject administered or was administered a prescribed daily dose over various periods, for the treatment of their infection. Subjects were requested to provide their background information and keep a record of the results of treatment.

Various symptoms of viral diseases were displayed by the subjects prior to treatment and included various skin disorders, Asthma, Bronchitis, Flu & Colds including general tiredness and other flu symptoms, and emphysema to name a few. Although subjects were subjected to differing doses and differing durations of treatment most subjects showed a marked improvement by a diminishing if no complete clearing of symptoms.

Several subjects had previously been treated with other types of medication or methods of treatment without much success. Treatment with the composition of the instant invention rapidly obviated symptoms displayed by most subjects, and most subjects no longer needed to rely on previous medication. As an example one subject suffering from Asthma stated that he no longer used his inhaler.

During the initial stages of treatment, several subjects had at least one side effect. The most common side effect displayed by subjects was a nasal discharge. Other side effects include acne out breaks on the back and on the head or phlegm and mucus discharges.

In most circumstances such side effects lasted a short period after which both the symptoms of the side effect and the original symptoms disappeared. The dosage administered to subjects varied depending on symptoms and subject age. The age of the group of subjects varied from 4' 2 years to 78 years.

Several of the records provided from subjects were completed by medical doctors, which provided a more expert opinion on the symptoms, side effects and results.

The mixture was administered to human subjects on a daily basis. Each subject administered a prescribed daily dose to themselves over various periods, for the treatment of their infection. Subjects were requested to provide their background information and results of treatment.

The various symptoms displayed by the subjects prior to treatment included various skin disorders, Asthma, Bronchitis, Flue and colds including general tiredness and other flu type symptoms, emphysema, prostrate cancer, diabetes to name a few. Although subjects were subjected to differing durations of treatment, most subjects showed a marked improvement by a diminishing if not complete clearing of symptoms.

Several subjects had been treated with other types of medication or methods of treatment without much success. Treatment with the composition of the instant invention rapidly obviated symptoms displayed by most subjects, and most subjects did not need to rely on other earlier used medication. One subject suffering from Asthma stated that he no longer used his inhaler. Although during the initial stages of treatment, several subjects had at least one side effect. The most common side effect displayed by subjects was a nasal discharge. Other side effects include acme outbreaks on the body and on the head or phlegm and mucus discharges. In most circumstances such side effects lasted a short period after which both the symptoms of the side effect and the original symptoms disappeared.

The dosage administered to subjects varied depending on symptoms and subject age. The age of the group of subjects ranged from 4V. to 78 years.

Several of the records provided from subjects were completed by medical doctors. The most preferred form of the present invention for human usage is a composition as follows:

Caffeine (Anhydrous) about 2.0g/100ml

Potassium Iodide about 2.0g/100ml

Ammonium Chloride about 2.0g/100ml M Meetthhyyll PPaarraabbeenn aabboouutt lOOmg/lOOml Isopropyl Paraben about 50mg/100ml Glycuol BP about 12.5g/100ml Syrupus BP about 40g 100ml Alcohol WS 95 about 5.7g 100ml, and GGrreeeenn NNoo..55 11%% ssoollnn aabboouutt 0.5g/100ml.

The composition has the following physical characteristic green solution with viscosity slightly greater than water.

Recommended optimum daily dosage is lml/6Kg body weight per Kg of patient. Initial dosages are to extent tolerated by patient with gradual (preferably weekly) increase to the optimum level. A suggested start may be as low as 2mls per patient.

Claims

CLAIMS:

1. A medicament comprising or including Caffeine (Anhydrous) about 2.0g/100ml Potassium Iodide about 2.0g/ 100ml and Ammonium Chloride about 2.0g/100ml.

2. A medicament of claim 1 which comprises or includes Caffeine (Anhydrous) about 2.0g/100ml Potassium Iodide about 2.0g 100ml Ammonium Chloride about 2.0g/100ml Methyl Paraben about lOOmg/lOOml and Isopropyl Paraben about 50mg/100ml.

3. A medicament of claim 1 which comprises or includes Caffeine (Anhydrous) about 2.0g 100ml Potassium Iodide about 2.0g/100ml Ammonium Chloride about 2.0g/100ml Methyl Paraben about lOOmg/lOOml Isopropyl Paraben about 50mg/100ml

Glycuol BP about 12.5g/100ml

Syrupus BP about 40g/100ml

Alcohol WS 95 about 5.7g/100ml

Green No.5 1% soln about 0.5g/100ml

4. A medicament suitable for the treatment of mammals for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated and/or for the use as a detoxicant mixture with any such mammal, said medicament comprising or including

Caffeine (Anhydrous) about 20g/L Potassium Iodide about 20g L and

Ammonium Chloride about 20g L.

5. A medicament of claim 4 which also includes: methyl paraben and isopropyl paraben together with compatible carriers and orally acceptable inclusions.

6. A method of treating a human or mammal for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated and/or for detoxifying such a mammal, said method comprising the steps of periodically administering or having administered to such a mammalian patient an effective amount of a medicaments) comprising caffeine (anhydrous) about 20g/L, potassium iodide about 20g/L and ammonium chloride about 20g L.

7. A method of claim 6 wherein said medicament(s) also includes or include methyl paraben and isopropyl paraben together with optionally compatible carriers and orally acceptable inclusions.

8. A method of claim 6 or 7 wherein daily optimum dosages of the medicaments) is or are administered only after a lead up period of lower dosing.

9. A method of claim 6, 7 or 8 wherein for a human patient a daily optimum dosage of about lml/6Kg of body weight is administered daily after a lead up period of lower dosing.